Pediatric Infectious Disease

Register      Login

VOLUME 6 , ISSUE 4 ( October-December, 2024 ) > List of Articles

Original Article

Automated Detection and Antifungal Susceptibility Profile of Candida Species Isolated from Blood Cultures of Neonatal ICU Patients Using MALDI-TOF and VITEK: Insights from a Tertiary Care Center in Rajasthan

Mamta Lamba, Vijaylaxmi Meena, Rekha Bachhiwal, Rajni Sharma

Keywords : Antifungal, Automation, Candida, Matrix-assisted laser desorption ionization time-of-flight, Neonates

Citation Information : Lamba M, Meena V, Bachhiwal R, Sharma R. Automated Detection and Antifungal Susceptibility Profile of Candida Species Isolated from Blood Cultures of Neonatal ICU Patients Using MALDI-TOF and VITEK: Insights from a Tertiary Care Center in Rajasthan. Pediatr Inf Dis 2024; 6 (4):111-114.

DOI: 10.5005/jp-journals-10081-1442

License: CC BY-NC 4.0

Published Online: 05-11-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Aims and background: Accurate identification of Candida species and their antifungal susceptibility (AFS) profiles, especially in neonates, is important in the era of emerging pathogens like Candida and the growing resistance to commonly used antifungal agents. This study aimed to accurately identify Candida species using automated identification systems, specifically matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Additionally, we assessed the AFS patterns of these isolates using the automated VITEK 2 Compact system. Materials and methods: This prospective study was conducted in the Department of Microbiology at SMS Medical College, Jaipur, Rajasthan, from April 2023 to August 2023. Blood culture samples were processed using the automated BacT/Alert system, followed by Gram staining and inoculation onto blood agar and MacConkey agar. Gram results were communicated to the clinicians on the same day. Smears showing budding yeast cells were further analyzed using MALDI-TOF MS for species identification, and their minimal inhibitory concentrations (MICs) were determined using the VITEK 2 Compact system. Results: Among 161 Candida isolates, Candida krusei emerged as the most prevalent species (35%), followed by C. tropicalis (20%) and C. glabrata (15%). Male children constituted 69% of the total cases. Voriconazole demonstrated the highest sensitivity (86%), followed by micafungin (84%), caspofungin (79%), and amphotericin B (78%). Conversely, 5-flucytosine exhibited the lowest susceptibility (35%), along with fluconazole (49%). Conclusion: Identification of yeasts from blood culture by automated systems like MALDI-TOF and VITEK 2 is a fast, reliable technique, offering clinicians timely and precise information crucial for prompt patient management and targeted treatment strategies. Clinical significance: C. krusei has emerged as the most prevalent species in neonates amid the increasing trend of C. tropicalis over the past few years. We have adopted technologies like MALDI-TOF MS and VITEK 2 systems for prompt identification of Candida species, thereby speeding up the diagnosis and providing early reports to clinicians, ultimately saving the lives of neonates.


HTML PDF Share
  1. Hassan I, Powell G, Sidhu M, et al. Excess mortality, length of stay and cost attributable to candidaemia. J Infect 2009;59(5):360–365. DOI: 10.1016/j.jinf.2009.08.020
  2. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 2014;20(Suppl 6):5–10. DOI: 10.1111/1469-0691.12539
  3. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20(1):133–163. DOI: 10.1128/CMR.00029-06
  4. Kathuria S, Singh PK, Sharma C, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile vari- ability by Vitek 2, CLSI broth microdilution, and etest method. J Clin Microbiol 2015;53(6):1823–1830. DOI: 10.1128/JCM.00367-15
  5. Kim SH, Shin JH, Mok JH, et al. Misidentification of Candida guilliermondii as C. famata among strains isolated from blood cultures by the VITEK 2 system. BioMed Res Int 2014;2014:250408. DOI: 10.1155/2014/250408
  6. Lamba M, Sharma D, Sharma R, et al. To study the profile of Candida isolates and antifungal susceptibility pattern of neonatal sepsis in a tertiary care hospital of North India. J Matern Fetal Neonatal Med 2021;34(16):2655–2659. DOI: 10.1080/14767058.2019.1670799
  7. Golia S, Reddy KM, Karjigi KS, et al. Speciation of Candida using chromogenic and cornmeal agar with determination of fluconazole sensitivity. Al Ameen J Med Sci 2013;6(2):163–166.
  8. Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag 2014;10:95–105. DOI: 10.2147/TCRM.S40160
  9. Murray PR, Rosenthal KS, Pfaller MA, editors. Fırsatçı Mikozlar. Çeviri: AC Başustaoğlu. In: Murray PR, Rosenthal KS, Pfaller MA, editors. Tıbbi Mikrobiyoloji. 6th ed. Ankara: Atlas Kitapçılık; 2010. pp. 751–759.
  10. Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012;50(4):1199–1203. DOI: 10.1128/JCM.06112-11
  11. Alkharashi N, Aljohani S, Layqah L, et al. Candida bloodstream infection: changing pattern of occurrence and antifungal susceptibility over 10 years in a Tertiary Care Saudi Hospital. Can J Infect Dis Med Microbiol 2019;2019:2015692. DOI: 10.1155/2019/2015692
  12. Barton M, O'Brien K, Robinson JL, et al. Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls. BMC Infect Dis 2014;14:327. DOI: 10.1186/1471-2334-14-327
  13. Amaral-Lopes S, Moura A. Neonatal fungal sepsis by Candida krusei: a report of three cases and a literature review. Med Mycol Case Rep 2012;1:24–26. DOI: 10.1016/j.mmcr.2012.04.002
  14. Choi HK, Jeong SJ, Lee HS, et al. Blood stream infections by Candida glabrata and Candida krusei: a single-center experience. Korean J Intern Med 2009;24:263–269. DOI: 10.3904/kjim.2009.24.3.263
  15. Abbas J, Bodey GP, Hanna HA, et al. Candida krusei fungemia: an escalating serious infection in immunocompromised patients. Arch Intern Med 2000;160:2659–2664. DOI: 10.1001/archinte.160.17.2659
  16. Rongpharpi SR, Gur R, Duggal S, et al. Candida krusei fungemia in 7 neonates: clonality tracked to an infusate. Am J Infect Control 2014;42(11):1247–1248. DOI: 10.1016/j.ajic.2014.07.033
  17. García-Rodas R, González-Camacho F, Rodríguez-Tudela JL, et al. The interaction between Candida krusei and murine macrophages results in multiple outcomes including intracellular survival and escape from killing. Infect Immun 2011;79:2136–2144. DOI: 10.1128/IAI.00044-11
  18. DiazGranados CA, Martinez A, Deaza C, et al. An outbreak of Candida spp bloodstream infection in a tertiary care centre in Bogotá, Colombia. Braz J Infect Dis 2008;12:390–394. DOI: 10.1590/s1413-86702008000500009
  19. Kean R, Brown J, Gulmez D, et al. Candida auris: a decade of understanding of an enigmatic pathogenic yeast. J Fungi (Basel) 2020;6(1):30. DOI: 10.3390/jof6010030
  20. Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 2017;13(5):e1006290. DOI: 10.1371/journal.ppat.1006290
  21. Gupta A, Gupta A, Varma A. Candida glabrata candidemia: an emerging threat in critically ill patients. Indian J Crit Care Med 2015;19(3):151–154. DOI: 10.4103/0972-5229.152757
  22. Goldman M, Pottage JC Jr, Weaver DC. Candida krusei fungemia. Report of 4 cases and review of the literature. Medicine (Baltimore) 1993;72(3):143–150.
  23. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100(6):617–623. DOI: 10.1016/s0002-9343(95)00010-0
  24. Merz WG, Karp JE, Schron D, et al. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol 1986;24(4):581–584. DOI: 10.1128/jcm.24.4.581-584.1986
  25. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002;50:243–260. DOI: 10.1053/jhin.2001.1151
  26. Berrouane YF, Hollis RJ, Pfaller MA. Strain variation among and antifungal susceptibilities of isolates of Candida krusei. J Clin Microbiol 1996;34:1856–1858. DOI: 10.1128/JCM.34.7.1856-1858.1996
  27. Majoros L, Szegedi I, Kardos G, et al. Slow response of invasive Candida krusei infection to amphotericin B in a clinical time-kill study. Europ J Clin Microbiol Infect Dis 2006;25:803–806. DOI: 10.1007/s10096-006-0200-5
  28. Olver WJ, Scott F, Shankland S. Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin. Med Mycol 2006;44:655–657. DOI: 10.1080/13693780600686929
  29. Jamiu AT, Albertyn J, Sebolai OM, et al. Update on Candida krusei, a potential multidrug-resistant pathogen. Med Mycol 2021;59(1):14–30. DOI: 10.1093/mmy/myaa031
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.